Novasep bets $11M on armed antibody R&D

French contract drugmaker Novasep is investing €10 million ($11 million) to build an antibody-drug conjugate facility at its Le Mans outpost. The new operation will offer bioconjugation services for the production of ADCs, which work by attaching a drug to a homing antibody, allowing for targeted delivery. Novasep expects to bring the facility online in the second quarter of next year. More

Suggested Articles

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.

The CRO will transfer most of its Pennsylvania-based biologics laboratory functions to a new, 73,000-square-foot site on Devon Park in Wayne.

Monoclonal antibodies developer Xencor extended a strategic alliance formed in 2016 with Selexis with four commercial license agreements.